Drug Profile
VGX 3400
Alternative Names: VGX-3400X; VGX™-3400Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer GeneOne Life Science; Inovio Pharmaceuticals
- Class DNA vaccines; Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in South Korea (IM, Injection)
- 28 May 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in South Korea (IM, Injection)
- 28 May 2018 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in USA (IM, Injection)